|
Neoplasms
|
0.080 |
Biomarker
|
group |
BEFREE |
Selection in G418-containing medium produced CTLLR8 transfectant clones that: (1) expressed chimeric Fc(epsilon) receptor as determined by flow cytometry; (2) bound human IgE antibodies with high affinity as determined by Scatchard analysis; (3) specifically rosetted IgE-coated SRBC; (4) lysed target cells in IgE-mediated ADCC and reverse ADCC assays; and (5) retarded tumor growth in a Winn assay.
|
8975874 |
1996 |
|
Lung Neoplasms
|
0.020 |
AlteredExpression
|
group |
LHGDN |
Inactivation of human SRBC, located within the 11p15.5-p15.4 tumor suppressor region, in breast and lung cancers.
|
11691816 |
2001 |
|
Malignant neoplasm of lung
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Inactivation of human SRBC, located within the 11p15.5-p15.4 tumor suppressor region, in breast and lung cancers.
|
11691816 |
2001 |
|
Neoplasms
|
0.080 |
GeneticVariation
|
group |
BEFREE |
Recently, the human SRBC (hSRBC) gene, a candidate tumor suppressor gene (TSG), has been mapped to the chromosomal region 11p 15.5--p15.4 where frequent allele loss has been described in lung cancer.
|
15940253 |
2005 |
|
Lung Neoplasms
|
0.020 |
AlteredExpression
|
group |
LHGDN |
Expression of the candidate tumor suppressor gene hSRBC is frequently lost in primary lung cancers with and without DNA methylation.
|
15940253 |
2005 |
|
Malignant neoplasm of lung
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Normal hSRBC protein expression was detected in only 18% of primary NSCLCs (N=93) by immunostaining and a significant association between loss of protein expression and methylation was found. hSRBC re-expression was observed after treatment of lung cancer cells with the demethylating agent 5-aza-2'-deoxycytidine.
|
15940253 |
2005 |
|
Carcinoma of lung
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Normal hSRBC protein expression was detected in only 18% of primary NSCLCs (N=93) by immunostaining and a significant association between loss of protein expression and methylation was found. hSRBC re-expression was observed after treatment of lung cancer cells with the demethylating agent 5-aza-2'-deoxycytidine.
|
15940253 |
2005 |
|
Primary malignant neoplasm of lung
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Normal hSRBC protein expression was detected in only 18% of primary NSCLCs (N=93) by immunostaining and a significant association between loss of protein expression and methylation was found. hSRBC re-expression was observed after treatment of lung cancer cells with the demethylating agent 5-aza-2'-deoxycytidine.
|
15940253 |
2005 |
|
Neoplasms
|
0.080 |
PosttranslationalModification
|
group |
BEFREE |
Our findings suggest that hSRBC is a novel tumor suppressor whose epigenetic inactivation contributes to the malignant progression of gastric tumors, in part, through attenuated p53 response to stresses.
|
18059034 |
2008 |
|
Carcinogenesis
|
0.030 |
AlteredExpression
|
phenotype |
BEFREE |
To explore the candidacy of hSRBC as a suppressor of gastric tumorigenesis, we analyzed the expression and mutation status of hSRBC in gastric tissues and cell lines. hSRBC transcript was expressed in all normal and benign tumor tissues examined, but undetectable or very low in 73% (11/15) cancer cell lines and 41% (46/111) primary tumors.
|
18059034 |
2008 |
|
Malignant Neoplasms
|
0.010 |
AlteredExpression
|
group |
BEFREE |
To explore the candidacy of hSRBC as a suppressor of gastric tumorigenesis, we analyzed the expression and mutation status of hSRBC in gastric tissues and cell lines. hSRBC transcript was expressed in all normal and benign tumor tissues examined, but undetectable or very low in 73% (11/15) cancer cell lines and 41% (46/111) primary tumors.
|
18059034 |
2008 |
|
Malignant neoplasm of stomach
|
0.010 |
PosttranslationalModification
|
disease |
BEFREE |
Frequent epigenetic inactivation of hSRBC in gastric cancer and its implication in attenuated p53 response to stresses.
|
18059034 |
2008 |
|
Stomach Neoplasms
|
0.010 |
PosttranslationalModification
|
group |
BEFREE |
Our findings suggest that hSRBC is a novel tumor suppressor whose epigenetic inactivation contributes to the malignant progression of gastric tumors, in part, through attenuated p53 response to stresses.
|
18059034 |
2008 |
|
Stomach Carcinoma
|
0.010 |
PosttranslationalModification
|
disease |
BEFREE |
Frequent epigenetic inactivation of hSRBC in gastric cancer and its implication in attenuated p53 response to stresses.
|
18059034 |
2008 |
|
Primary malignant neoplasm
|
0.010 |
AlteredExpression
|
group |
BEFREE |
To explore the candidacy of hSRBC as a suppressor of gastric tumorigenesis, we analyzed the expression and mutation status of hSRBC in gastric tissues and cell lines. hSRBC transcript was expressed in all normal and benign tumor tissues examined, but undetectable or very low in 73% (11/15) cancer cell lines and 41% (46/111) primary tumors.
|
18059034 |
2008 |
|
Carcinogenesis
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
To explore the implication of human SRBC gene [serum deprivation response factor-related gene product that binds to the c-kinase (hSRBC)] abnormality in ovarian tumorigenesis.
|
20423276 |
2010 |
|
Neoplasms
|
0.080 |
AlteredExpression
|
group |
BEFREE |
PRKCDBP was induced by TNFα, and its level correlated with tumor cell sensitivity to TNFα-induced apoptosis.
|
21980136 |
2011 |
|
Carcinogenesis
|
0.030 |
AlteredExpression
|
phenotype |
BEFREE |
We investigated expression and function of PRKCDBP in colorectal cells and tissues to explore its candidacy as a suppressor in colorectal tumorigenesis.
|
21980136 |
2011 |
|
Colorectal Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
PRKCDBP is a proapoptotic tumor suppressor which is commonly altered in colorectal cancer by promoter hypermethylation, and its gene transcription is directly activated by NF-κB in response to TNFα.
|
21980136 |
2011 |
|
Malignant neoplasm of colon and/or rectum
|
0.020 |
Biomarker
|
disease |
BEFREE |
PRKCDBP is a proapoptotic tumor suppressor which is commonly altered in colorectal cancer by promoter hypermethylation, and its gene transcription is directly activated by NF-κB in response to TNFα.
|
21980136 |
2011 |
|
Neuroblastoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
In our study, a low methylation frequency of SCNN1A, PRKCDBP and KRT19 is significantly associated with favorable outcome in neuroblastoma.
|
21314941 |
2011 |
|
Tumor Progression
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
This suggests that PRKCDBP inactivation may contribute to tumor progression by reducing cellular sensitivity to TNFα and other stresses, particularly under chronic inflammatory microenvironment.
|
21980136 |
2011 |
|
Central neuroblastoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
In our study, a low methylation frequency of SCNN1A, PRKCDBP and KRT19 is significantly associated with favorable outcome in neuroblastoma.
|
21314941 |
2011 |
|
Childhood Neuroblastoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
In our study, a low methylation frequency of SCNN1A, PRKCDBP and KRT19 is significantly associated with favorable outcome in neuroblastoma.
|
21314941 |
2011 |
|
Neoplasms
|
0.080 |
Biomarker
|
group |
BEFREE |
As caveolin-1 and cavin family proteins are required for caveolae formation and function, the reported tumor suppression function of caveolin-1 and SRBC may be due to the deregulation of caveolae and its down-stream signaling.
|
21913217 |
2012 |